Board approved audited standalone and consolidated financial results for Q4 and FY ended 31-Mar-2026, with statutory auditors issuing an unmodified opinion.
Standalone net profit for FY26 stood at ₹137.72 crore, up 36.3% YoY from ₹101.00 crore in FY25, with revenue from operations at ₹2,319.06 crore.
Approved two capacity expansion projects at Barnala plant: new 6000 MTPA Triacetin manufacturing facility and Pantoprazole capacity increase from 240 to 276 MTPA, both funded through internal accruals.
Fixed the 39th Annual General Meeting on 2nd September 2026 and noted the striking off of subsidiary IOL Life Sciences Limited effective 1st April 2026.